Industry
Biotechnology
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Loading...
Open
8.86
Mkt cap
371M
Volume
63K
High
8.92
P/E Ratio
-3.01
52-wk high
18.40
Low
8.38
Div yield
N/A
52-wk low
4.42
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 9:39 am
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 10:35 am
Portfolio Pulse from Vaishali Prayag
June 14, 2024 | 6:26 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 4:32 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 1:27 pm
Portfolio Pulse from Benzinga Newsdesk
April 15, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 3:06 pm
Portfolio Pulse from Benzinga Newsdesk
March 11, 2024 | 9:41 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.